FDA Approves Inovio Treatment; Shares More Than Triple Premarket
The FDA approved an Inovio treatment for a rare respiratory condition. Inovio shares more than tripled premarket.
Related stories
Fujian Wanchen Food Group Placed Under Regulatory Investigation
M impact | REGULATION | Nov 02, 2026, 11:02 AM UTC
FDA Grants Accelerated Approval to Inovio’s VOCERYQ
The FDA approved the immunotherapy to reduce surgery frequency in adults with recurrent respiratory papillomatosis.
M impact | REGULATION | Nov 02, 2026, 10:57 AM UTC
Inovio Gets FDA Nod for Rare Throat Disease
Shares of Inovio Pharmaceuticals jump after an FDA nod for a rare throat disease.
M impact | REGULATION | Nov 02, 2026, 10:48 AM UTC
Japan Weighs Doubling Defense Spending, Sources Say
Japan is considering doubling its defense spending, according to sources cited by Reuters.
L impact | REGULATION | Nov 02, 2026, 10:36 AM UTC
China Central Bank Uses Liquidity Tool to Support Stocks
M impact | REGULATION | Nov 02, 2026, 10:21 AM UTC
China’s central bank to conduct swap operations to support stocks
The People’s Bank of China said it will conduct swap operations with financial institutions on Tuesday that could inject more than 100 billion yuan ($15.04 billion) into the stock
M impact | REGULATION | Nov 02, 2026, 10:21 AM UTC